Research Article
PLOS ONE | DOI:10.1371/journal.pone.0169530 February 16, 2017
Информационный бюллетень содержит краткое изложение новой стратегии Глобального фонда, опыта, накопленного в ходе первого цикла финансирования на основе выделен...ия ресурсов, приоритетных направлений профилактики ТБ, реализации программ по уходу и лечению и включает рекомендации по определению или выявлению основных затронутых или уязвимых к туберкулезу групп населения и выбору приоритетных с точки зрения достижения наибольшего воздействия мероприятий по ТБ.
more
2016 data
The report was coordinated by Anastasia Pharris and Annemarie Stengaard.
Report review and production support were provided by Andrew J. Amato-Gauci, Mike Catchpole, Denis Coulombier, Masoud Dara, Nedret Emiroglu, Rachel Katterl, Shahin Khasiyev, Valentina Lazdina, Teymur Noori, Marc... Rondy, Chantal Quintin, Phillip Zucs.
more
Vol. 7, No. 1 (2018) | ISSN 2166-7403 (online) DOI 10.5195/cajgh.2018.295 | http://cajgh.pitt.edu
PLOS ONE | www.plosone.org
September 2014 | Volume 9 | Issue 9 | e103657
braz j infect dis. 2014;18(5):491–495
http://dx.doi.org/10.1016/j.bjid.2014.02.004
1413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
Specific Issues and a Model of Care
Accessed; 08.10.2019
Prepared by the monitoring and learning unit
Борьба с туберкулезом представляет собой одну из ведущих областей, в которых ведется регулярный сбор информации, которая измеряет самые критические показатели вы...ходных данных и результатов, используемые при составлений отчетов на уровне отдельных стран и всего мира.
more
Child Survival Working Group
Accessed: 18.10.2019
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Supplement Article
J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018 www.jaids.com
Revised working paper following AVAREF meeting February 2019.
WHO has published a roadmap aiming to coordinate partners’ actions and contributions to the licensing and roll-out of Merck’s Ebola vaccine (VSV-ZEBOV) in African countries. The vaccine was developed during the West Africa Ebola epi...demic of 2014-2016, during which more than 11 000 people lost their lives to the disease. The vaccine was tested in European and African countries at the time and is currently used under an “expanded access” protocol in the Democratic Republic of Congo.
WHO will expedite prequalification and licensing of the vaccine for use in countries at risk of Ebola outbreaks and will coordinate work between those countries’ regulatory authorities and the European Medicines Agency and the US Food and Drug Administration.
more
All In #EndAdolescentAIDS
Global Webinar: Novel Approaches for Addressing Age of Consent as a Barrier to Adolescents' Care Utilization and Engagement
Accessed: 26.10.2019
Child Survival Working Group
Accessed: 26.10.2019
HIV Diagnostics
Information Note
WHO/HIV/2017.16